Targeting disordered proteins with small molecules using entropy

Trends in Biochemical Sciences

Volumn 40, Issue 9, 2015, Pages 491-496

  Heller, Gabriella T ^a   Sormanni, Pietro ^a   Vendruscolo, Michele ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Binding; Disordered proteins; Entropic expansion; Entropy; Small molecule

Indexed keywords

AMYLOID BETA PROTEIN; MYC PROTEIN; PROTEIN; PROTEIN BINDING;

ALZHEIMER DISEASE; BINDING AFFINITY; BINDING SITE; ENTHALPY; ENTROPY; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; THERMODYNAMICS; CHEMISTRY; PROTEIN CONFORMATION;

ENTROPY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; THERMODYNAMICS;

EID: 84940467045     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.07.004     Document Type: Review

References (56)

1. Griffith M., et al. DGIdb: mining the druggable genome. Nat. Methods 2013, 10:1209-1210.
2. Russ A.P., Lampel S. The druggable genome: an update. Drug Discov. Today 2005, 10:1607-1610.
3. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1:727-730.
4. Babu M.M., et al. Intrinsically disordered proteins: regulation and disease. Curr. Opin. Struct. Biol. 2011, 21:432-440.
5. Tompa P. Intrinsically disordered proteins: A 10-year recap. Trends Biochem. Sci. 2012, 37:509-516.
6. Metallo S.J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 2010, 14:481-488.
7. Uversky V.N., et al. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys. 2008, 37:215-246.
8. Dunker A.K., et al. Intrinsic protein disorder in complete genomes. Genome Inform. Ser. Workshop Genome Inform. 2000, 11:161-171.
9. Dunker A.K., et al. Intrinsic disorder and protein function. Biochemistry 2002, 41:6573-6582.
10. Sormanni P., et al. The s2D method: simultaneous sequence-based prediction of the statistical populations of ordered and disordered regions in proteins. J. Mol. Biol. 2015, 427:982-996.
11. Flock T., et al. Controlling entropy to tune the functions of intrinsically disordered regions. Curr. Opin. Struct. Biol. 2014, 26:62-72.
12. Dyson H.J., Wright P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 2005, 6:197-208.
13. Tompa P., Han K. Intrinsically disordered proteins. Phys. Today 2012, 65:64.
14. Wright P.E., Dyson H.J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 1999, 293:321-331.
15. Uversky V.N. Intrinsically disordered proteins from A to Z. Int. J. Biochem. Cell Biol. 2011, 43:1090-1103.
16. Habchi J., et al. Introducing protein intrinsic disorder. Chem. Rev. 2014, 114:6561-6588.
17. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
18. Rafii M.S., Aisen P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7:7.
19. Cohen S.I., et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9758-9763.
20. Tóth G., et al. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS ONE 2014, 9:e87133.
21. Hammoudeh D.I., et al. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 2009, 131:7390-7401.
22. Follis A.V., et al. Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg. Med. Chem. Lett. 2009, 19:807-810.
23. Berg T. Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr. Top. Microbiol. Immunol. 2010, 348:139-149.
24. Cuchillo R., Michel J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem. Soc Trans. 2012, 40:1004-1008.
25. Marlow M.S., et al. The role of conformational entropy in molecular recognition by calmodulin. Nat. Chem. Biol. 2010, 6:352-358.
26. Bronowska A. Thermodynamics of ligand-protein interactions: implications for molecular design. Thermodynamics - Interaction Studies - Solids, Liquids and Gases 2011, 1-49. InTech. J.C. Moreno-Pirajan (Ed.).
27. Klebe G. Applying thermodynamic profiling in lead finding and optimization. Nat. Rev. Drug Discov. 2015, 14:95-110.
28. Chodera J.D., Mobley D.L. Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. Annu. Rev. Biophys. 2013, 42:121-142.
29. Liu T., et al. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007, 35(Suppl. 1):D198-D201.
30. Chen X., et al. The Binding Database: overview and user's guide. Biopolymers 2001, 61:127-141.
31. Chen X., et al. The Binding Database: data management and interface design. Bioinformatics 2002, 18:130-139.
32. Chen X., et al. BindingDB: a web-accessible molecular recognition database. Comb. Chem. High Throughput Screen. 2001, 4:719-725.
33. 2+ binding properties of novel C2 domains of plant phospholipase Dα and β. J. Biol. Chem. 2000, 275:19700-19706.
34. Prorok M., Castellino F.J. Thermodynamics of binding of calcium, magnesium, and zinc to the N- methyl-D-aspartate receptor ion channel peptidic inhibitors, conantokin-G and conantokin-T. J. Biol. Chem. 1998, 273:19573-19578.
35. Crespo A., Fernández A. Induced disorder in protein-ligand complexes as a drug-design strategy. Mol. Pharm. 2008, 5:430-437.
36. Diehl C., et al. Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3. J. Am. Chem. Soc. 2010, 132:14577-14589.
37. Frederick K.K., et al. Conformational entropy in molecular recognition by proteins. Nature 2007, 448:325-329.
38. Chang C-E.A., et al. Entropic contributions and the influence of the hydrophobic environment in promiscuous protein-protein association. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7456-7461.
39. Baron R., McCammon J.A. (Thermo)dynamic role of receptor flexibility, entropy, and motional correlation in protein-ligand binding. ChemPhysChem 2008, 9:983-988.
40. Tzeng S-R., Kalodimos C.G. Dynamic activation of an allosteric regulatory protein. Nature 2009, 462:368-372.
41. Follis A.V., et al. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem. Biol. 2008, 15:1149-1155.
42. Mendgen T., et al. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J. Med. Chem. 2012, 55:743-753.
43. Wright P.E., Dyson H.J. Linking folding and binding. Curr. Opin. Struct. Biol. 2009, 19:31-38.
44. Michel J., Cuchillo R. The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-Myc. PLoS ONE 2012, 7:e41070.
45. Jin F., et al. Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins. PLoS Comput. Biol. 2013, 9:e1003249.
46. Michelsen K., et al. Ordering of the N-terminus of human MDM2 by small molecule inhibitors. J. Am. Chem. Soc. 2012, 134:17059-17067.
47. Bueren-Calabuig J.A., Michel J. Elucidation of ligand-dependent modulation of disorder-order transitions in the oncoprotein MDM2. PLoS Comput. Biol. 2015, 11:e1004282.
48. Xiang S., et al. Phosphorylation drives a dynamic switch in serine/arginine-rich proteins. Structure 2013, 21:2162-2174.
49. Camilloni C., Vendruscolo M. A relationship between the aggregation rates of α-synuclein variants and the β-sheet populations in their monomeric forms. J. Phys. Chem. B 2013, 117:10737-10741.
50. Hong W., et al. Periplasmic protein HdeA exhibits chaperone-like activity exclusively within stomach pH range by transforming into disordered conformation. J. Biol. Chem. 2005, 280:27029-27034.
51. Porcari R., et al. The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein. J. Biol. Chem. 2015, 290:2395-2404.
52. Jeong K-C., et al. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest. Mol. Biosyst. 2010, 6:1503-1509.
53. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8:101-112.
54. Knowles T.P.J. An analytical solution to the kinetics of breakable filament assembly. Science 2009, 1533:1533-1537.
55. Uversky V.N., et al. Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics 2009, 10(Suppl. 1):S7.
56. Giandanti A.D. On the abundance of intrinsically disordered proteins in the human proteome and its relation to diseases: there is no enrichment. Biophys. Bioeng. Lett. 2014, 7:27-32.